Search CTL/CD8+ T-Cell Epitope Database

Found 8 matching records:

Displaying record number 59001

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif(101-)
Epitope	`GLADQLIHL`	Epitope Alignment
Epitope Name	Vif101
Subtype	A
Species (MHC/HLA)	human(A*02)
Immunogen	HIV-1 infection, vaccine
Country	Guinea-Bissau
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	vaccine-induced immune responses, vaccine antigen design, therapeutic vaccine, chronic infection

Vaccine Details

Vaccine type	peptide
Vaccine strain	A clade
Adjuvant	CAF01

Notes

Therapeutic vaccination of chronically infected HIV-1 subjects was evaluated as a means of halting disease progression. A subdominant peptide vaccine containing 15 CTL epitopes and 3 helper T-cell peptides along with an adjuvant was delivered to 18 infected subjects, and this Guinea-Bissau study compared to a similar Danish one. Using IFN-γ EliSpot, 9 new T-cell responses were detected in 6/14 subjects whose viral loads (VL) remained stable. Other pre-existing responses, including CTL responses, however, were not significantly detected.
Vif101, GLADQLIHL, is a CTL epitope sequence used as a vaccine component.

References

Roman2013 Victor Raúl Gómez Román, Kristoffer Jarlov Jensen, Sanne Skov Jensen, Christian Leo-Hansen, Sanne Jespersen, David da Silva Té, Candida Medina Rodrigues, Christoph Mikkel Janitzek, Lasse Vinner, Terese Lea Katzenstein, Peter Andersen, Ingrid Kromann, Lars Vibe Andreasen, Ingrid Karlsson, and Anders Fomsgaard. Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses, 29(11):1504-1512, Nov 2013. PubMed ID: 23634822. Show all entries for this paper.

Displaying record number 60945

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif(101-109)
Epitope	`GLADQLIHL`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection
Patient MHC/HLA	32645: A01:01, A02:01, B08:01, B35:03, C04:01, C07:01
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	acute/early infection

Notes

The extent to which set-point viremia is affected by early HIV-infection T cell responses to either conserved or variable epitopes was studied. 23 ART-naive subjects were characterized for CTL responses for 6 months, postinfection. While most CTL responses (73/123) were targeted against variable HIV-1 epitopes, recognition of conserved epitopes (16/123) was associated with lower set point viremia. This was independent of HLA type and also functional avidity of the CTL response. Most of the conserved responses were targeted to Gag and Pol epitopes.
GLADQLIHL, restricted by A*0201, was recognized by 1 patient with the restricting allele.

References

Kunwar2013 Pratima Kunwar, Natalie Hawkins, Warren L. Dinges, Yi Liu, Erin E. Gabriel, David A. Swan, Claire E. Stevens, Janine Maenza, Ann C. Collier, James I. Mullins, Tomer Hertz, Xuesong Yu, and Helen Horton. Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design. PLoS One, 8(5):e64405, 2013. PubMed ID: 23741326. Show all entries for this paper.

Displaying record number 57139

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif
Epitope	`GLADQLIHL`	Epitope Alignment
Epitope Name	Vif101 M9L
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection, vaccine
Country	Denmark
Experimental methods	Intracellular cytokine staining, Pentamer labeling
Keywords	vaccine-induced immune responses, therapeutic vaccine

Vaccine Details

Vaccine type	peptide
Vaccine strain	multiple epitope immunogen
Vaccine component	HIV-1, other

Notes

Several subdominant but conserved CD8+ and CD4+ T-cell epitopes were anchor-optimized delivered to 12 treatment-naive A*0201-positive HIV-1 patients. Previously-undetected responses specific for one or more epitopes were detected in all patients.
GLADQLIHL is an anchor-optimized variant of GLADQLIHm epitope. 2/12 patients showed a novel induced response after vaccination with GLADQLIHL.

References

Kloverpris2009a Henrik Kloverpris, Ingrid Karlsson, Jesper Bonde, Mette Thorn, Lasse Vinner, Anders E. Pedersen, Julie L. Hentze, Betina S. Andresen, Inge M. Svane, Jan Gerstoft, Gitte Kronborg, and Anders Fomsgaard. Induction of Novel CD8+ T-Cell Responses during Chronic Untreated HIV-1 Infection by Immunization with Subdominant Cytotoxic T-Lymphocyte Epitopes. AIDS, 23(11):1329-1340, 17 Jul 2009. PubMed ID: 19528789. Show all entries for this paper.

Displaying record number 57148

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif
Epitope	`GLADQLIHL`	Epitope Alignment
Epitope Name	Vif101(9L)
Species (MHC/HLA)	transgenic mouse(A*02:01)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Flow cytometric T-cell cytokine assay
Keywords	immunodominance, dendritic cells

Vaccine Details

Vaccine strain	multiple epitope immunogen
Vaccine component	Env, Gag, Pol, Vif, Vpu

Notes

Transgenic A*0201 mice were immunized with matured dendritic cells pulsed with 7 CTL peptides, singly or in combination. The magnitude of individual T-cell responses correlated with their individual immunogenicity.
Of the 7 epitopes tested, GLADQLIHL was ranked sixth in immunogenicity based on several assays.

References

Kloverpris2009 Henrik N. Kloverpris, Ingrid Karlsson, Mette Thorn, Søren Buus, and Anders Fomsgaard. Immune Hierarchy among HIV-1 CD8+ T Cell Epitopes Delivered by Dendritic Cells Depends on MHC-I Binding Irrespective of Mode of Loading and Immunization in HLA-A*0201 Mice. APMIS, 117(11):849-585, Nov 2009. PubMed ID: 19845536. Show all entries for this paper.

Displaying record number 52665

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif(101-)
Epitope	`GLADQLIHL`	Epitope Alignment
		Show epitope variants
Epitope Name	Vif101(9L)
Species (MHC/HLA)	human, transgenic mouse(A2)
Immunogen	HIV-1 infection, vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Flow cytometric T-cell cytokine assay
Keywords	binding affinity, subtype comparisons, computational epitope prediction

Vaccine Details

Vaccine type	peptide
Adjuvant	Incomplete Freund's Adjuvant (IFA)

Notes

HLA-A2-restricted HIV-1 CTL epitopes were computationally predicted. Binding affinities for HLA-A*0204, immunogenicity in HLA-A*0201 transgenic mice, and responses to the peptides in 17 HIV-1 infected patients were tested. 31 novel conserved A2 epitopes were detected. An average of 4 epitopes were recognized per patient.
This peptide was a good A2 binder that induced CTL and CD8+ T-cell IFN gamma responses in mice. Responses were detected in 3/17 HIV+ HLA-A2 subjects.
The variant gladqlihM was an intermediate A2 binder, but still could stimulate a response in HLA-A2 transgenic mice. It was not recognized by the 3 people who recognized with GLADQLIHL.

References

Corbet2003 Sylvie Corbet, Henrik Vedel Nielsen, Lasse Vinner, Sanne Lauemoller, Dominic Therrien, Sheila Tang, Gitte Kronborg, Lars Mathiesen, Paul Chaplin, Søren Brunak, Søren Buus, and Anders Fomsgaard. Optimization and Immune Recognition of Multiple Novel Conserved HLA-A2, Human Immunodeficiency Virus Type 1-Specific CTL Epitopes. J. Gen. Virol., 84(Pt 9):2409-2421, Sep 2003. PubMed ID: 12917462. Show all entries for this paper.

Displaying record number 58413

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif
Epitope	`GLADQLIHL`	Epitope Alignment
Epitope Name	Vif101
Subtype	B, CRF02_AG
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Country	Cote D'Ivoire, Denmark, Ghana, Guinea-Bissau, Mali, Senegal
Experimental methods	Intracellular cytokine staining, Pentamer labeling
Keywords	vaccine antigen design

Notes

15 subdominant CTL epitopes were used to study 2 new Guinea-Bissau HIV-1 isolates, a newly completed Danish subtype B genome sequence and other previously published West African sequences. Subtype analysis showed the 2 new Guinea-Bissau sequences were CRF02_AG inter-subtype recombinant forms with typical cross-over points. The 15 epitopes were restricted by common HLA alleles (A1, A2, A3, B7, B44) and were present and conserved in all sequences studied. Mean conservation of the epitopes in local strains was 76% and 70% for Denmark and West Africa respectively. All epitopes had been previously confirmed as antigenic [Corbet2003, Thorn2007, Perez2008, Kloverpris2009].
Vif101 epitope, GLADQLIHL, showed a conservation of amino acid identity of 56% for the Danish sequence and 65% for the West African sequences.

References

Perez2008 Carina L. Pérez, Mette V. Larsen, Rasmus Gustafsson, Melissa M. Norström, Ann Atlas, Douglas F. Nixon, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Broadly Immunogenic HLA Class I Supertype-Restricted Elite CTL Epitopes Recognized in a Diverse Population Infected with Different HIV-1 Subtypes. J. Immunol., 180(7):5092-5100, 1 Apr 2008. PubMed ID: 18354235. Show all entries for this paper.

Thorn2007 Mette Thorn, Sheila Tang, Dominic Therrien, Henrik Kløverpris, Lasse Vinner, Gitte Kronborg, Jan Gerstoft, Sylvie Corbet, and Anders Fomsgaard. Sequence Conservation of Subdominant HLA-A2-Binding CTL Epitopes in HIV-1 Clinical Isolates and CD8+ T-Lymphocyte Cross-Recognition May Explain the Immune Reaction in Infected Individuals. APMIS, 115(6):757-768, Jun 2007. PubMed ID: 17550385. Show all entries for this paper.

Vinner2011 Lasse Vinner, Birgitta Holmgren, Kristoffer J. Jensen, Joakim Esbjornsson, Marie Borggren, Julie L. Hentze, Ingrid Karlsson, Betina S. Andresen, Gregers J. Gram, Henrik Kloverpris, Peter Aaby, Zacarias José Da Silva, Eva-Maria Fenyö, and Anders Fomsgaard. Sequence Analysis of HIV-1 Isolates from Guinea-Bissau: Selection of Vaccine Epitopes Relevant in Both West African and European Countries. APMIS, 119(8):487-497, Aug 2011. PubMed ID: 21749448. Show all entries for this paper.

Displaying record number 56072

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location	Vif(101-)
Epitope	`GLADQLIHL`	Epitope Alignment
		Show epitope variants
Epitope Name	Vif 101 (9L)
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Country	Denmark
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	rate of progression, escape, acute/early infection

Notes

Comparative genetic and immunological study was conducted of two subjects - patient DK1 with no viremia for >10 years after transient ART and despite continued sexual contact with patient UG1 (his wife) who was an HIV-1-positive non-controller.
DK1 and UG1 shared most crossover points of recombination but while DK1 had subtype A1 Env, UG1's Env was subtype D. In the shared subtype A1/D regions, homology between the patients' sequences was 98%.
Out of 23 conserved HLA-A02 epitopes, HLA-A2+ DK1 produced CTL response and IFN-gamma response only to epitope ILKEPVHGV.
DK1 produced neutralizing antibody only to homologous isolates. It is suggested that early, transient ART may have resulted in full control of viremia and disease via the very narrow specific CTL response and neutralizing antibody.
Despite carrying HLA-A2, DK1 did not respond to HLA-A2 Vif epitope GLADQLIHL, though it did elicit response in a cohort of 11 other HIV-1+ HLA-A2+ patients. DK1 had variant sequence dLADQLIHL.

References

Fomsgaard2008 Anders Fomsgaard, Lasse Vinner, Dominic Therrien, Louise B. Jørgensen, Claus Nielsen, Lars Mathiesen, Court Pedersen, and Sylvie Corbet. Full-Length Characterization of A1/D Intersubtype Recombinant Genomes from a Therapy-Induced HIV Type 1 Controller during Acute Infection and His Noncontrolling Partner. AIDS Res. Hum. Retroviruses, 24(3):463-472, Mar 2008. PubMed ID: 18373434. Show all entries for this paper.

Displaying record number 55387

Download this epitope record as JSON.

HXB2 Location	Vif(101-109) DNA(5341..5367)	Vif Epitope Map
Author Location
Epitope	`GLADQLIHL`	Epitope Alignment
		Show epitope variants
Epitope Name	VIf 101(9L)
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Country	Denmark
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	variant cross-reactivity

Notes

11 HLA-A2+ (A*0201, A*0220, A*0234 or A*0236), patients' HIV were sequenced. Of 28 epitopes studied, most were conserved and elicited a subdominant CTL response. 9 epitopes in 7 proteins showed T-cell cross reaction. These epitopes were optimized to induce more immunogenic but cross-reacting responses.
Epitopes in Gag, Pol, Env, Nef were more conserved than epitopes in shorter proteins Vpu, Vif, Vpr and Rev. Most natural epitopes were untargeted or targeted by 1 or 2 patients.
Vif 101 (9L) GLADQLIHL epitope was not found in any patients but 2 patients had immune responses to it.
7 CTL cross-reacting variants were tested: they were L9I (GLADQLIHi), L9M (GLADQLIHm), G1S (sLADQLIHL), G1N (nLADQLIHL), G1D (dLADQLIHL), G1E (eLADQLIHL) and G1H.L9Q (hLADQLIHq). 8 of 11 patients cross-reacted with G1N and G1D. A2tg mice immunized with Vif101 also induced cross-reacting CTL to L9I, G1S, L9M and to a lesser extent to G1E, G1H.L9Q.
Vif101 (9L)-induced CTLs cross-reacted to Vif101 (9M) which though not found in any of the Danish isolates studied, is common worldwide among clade C (70%), clade D (35%) and clade H (33%) HIV-1-isolates.